Re: st: pk analysis suite: elementary questions about -pkequiv-, -pkcross-, and -pkshape-

["Joseph Coveney" <jcoveney@bigplanet.com>]

Michael McCulloch wrote:

Thank you kindly for the very helpful response and example.
You write "the potential for carryover effects (by whatever name) to  
confound crossover studies
is often more serious with outcomes other than chemical  
concentrations." Might you be able to recommend some reading (either  
published or online tutorials) on this issue in crossover studies?

--------------------------------------------------------------------------------

Outside of the biopharmaceutics-specific literature, the following reference
would be a good place to start:

Stephen J. Senn, _Cross-over Trials in Clinical Research_  Second Edition.
Chichester: John Wiley & Sons, 2002.


Online, there is a paper delivered at a SAS meeting some years ago:

http://www2.sas.com/proceedings/sugi24/Posters/p221-24.pdf

Its title comes across as a bit too negative, but the paper does touch on some
of the pitfalls in design and execution of a crossover study.

Joseph Coveney


*
*   For searches and help try:
*   http://www.stata.com/help.cgi?search
*   http://www.stata.com/support/statalist/faq
*   http://www.ats.ucla.edu/stat/stata/